IGF1R and neoplasm: An adult phase I combination of the anti-IGF1-R antibody cixutumumab and temsirolimus showed good tolerance and tumour regression of more than 20% in 5/17 (29%) EW patients who remained on study for 8 to 27 months, with a CR in 1/6 of EW patients who previously developed resistance to a different IGF-1R inhibitor antibody [36].